Ergoteles’s IGM Biosciences IGMS Stock Holding History

Ergoteles’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-38,500	Closed	-$694K	–	1730
2022 Q2	$694K	Buy	+38,500	New	+$686K	0.02%	698

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ergoteles's IGMS Position: Q3 2022 in Review

Ergoteles sold out of IGM Biosciences (IGMS) in Q3 2022, closing a stake of 38,500 shares — an estimated $694K sold.

Ergoteles first reported a position in IGMS in Q2 2022 and held it in 1 quarter. The position peaked at $694K in Q2 2022. 92 funds tracked by Wall St. Rank hold IGMS as of Q3 2022.

Ergoteles reported no remaining IGM Biosciences position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 38,500 IGM Biosciences shares in Q3 2022, an estimated $694K.
Ergoteles first reported a position in IGM Biosciences in Q2 2022 and held it in 1 quarter.
Ergoteles's IGM Biosciences position peaked at $694K in Q2 2022.
92 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.